Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy

Area of Science:

• Biochemistry
• Genetics
• Hepatology

Background:

• Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a fatal, autosomal recessive disorder.
• It results from mutations in the thymidine phosphorylase (TP) gene, causing TP deficiency.
• This deficiency leads to toxic nucleoside accumulation and mitochondrial DNA damage.

Observation:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a current treatment for MNGIE but has high mortality.
• The liver exhibits high thymidine phosphorylase expression.
• A 25-year-old patient with severe MNGIE underwent a liver transplant.

Findings:

• Serum toxic nucleoside levels normalized rapidly post-liver transplantation.
• The patient's clinical condition remained stable at 400 days of follow-up.
• Liver transplantation effectively restored thymidine phosphorylase activity.

Implications:

• Liver transplantation is a potential novel therapeutic strategy for MNGIE.
• This approach may offer a safer alternative to HSCT for MNGIE patients.
• Further research is warranted to validate liver transplantation for MNGIE treatment.